Y-Prime_Logo_rgb_color.png
YPrime Recognized as Trailblazer in Patient Engagement by Everest Group
September 24, 2024 08:42 ET | Y-Prime, LLC
YPrime has been recognized as a Trailblazer in patient engagement by Everest Group for its innovative solutions that enhance clinical trial participation.
bitmap-araris-logo-rgb (002).jpg
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)
September 24, 2024 08:00 ET | Araris Biotech
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...
NoomWSJ924adv10
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
September 24, 2024 07:02 ET | Noom Inc
Noom issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications.
Summit C3 wrap up
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
September 18, 2024 06:00 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
#4_Dr.Baz
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
September 17, 2024 08:48 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
#3_Dr. Cupler
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
September 17, 2024 04:29 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
#1 PLR-
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
September 16, 2024 14:06 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
23andMe_Logo_grey.png
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024 03:00 ET | 23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe_Logo_grey.png
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024 03:00 ET | 23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...
23andMe_Logo_grey.png
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET | 23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...